RheinCell Therapeutics GmbH has received Good Manufacturing Practice (GMP) certification and Manufacturing Authorization.
The certificate and accompanying manufacturing permit, which were granted following inspection of RheinCell’s manufacturing facilities in September 2020, confirm that the company's site follows the GMP principles of the European Union for human medicinal products (2003/94/EC), including requirements for chemical, physical, and biological quality control testing.
"We have reached another milestone in the evolution of our company – one that was borne from the foresight of our manufacturing and quality control teams, and the tremendous work of everyone involved in building an efficient production strategy," said Jürgen Weisser, CEO of RheinCell. "RheinCell is now one of very few commercial enterprises worldwide that are certified to produce iPSCs – a critical starting material for stem cell-based therapies – in a regulated and GMP-compliant process and environment."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
The GMP certification and Manufacturing Authorization pave the way for the company to deliver fully characterized clinical-grade iPSCs that are derived from human cord blood cells for the development of cell-based therapies.